rabeprazole sodium

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Gastroesophageal Reflux Disease

Conditions

Gastroesophageal Reflux Disease

Trial Timeline

Aug 1, 2005 → Jul 1, 2006

NCT ID

NCT00132496

About rabeprazole sodium

rabeprazole sodium is a phase 2 stage product being developed by Eisai for Gastroesophageal Reflux Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00132496. Target conditions include Gastroesophageal Reflux Disease.

What happened to similar drugs?

3 of 20 similar drugs in Gastroesophageal Reflux Disease were approved

Approved (3) Terminated (1) Active (17)

🔄Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3

🔄zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3

🔄zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3

🔄zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3

🔄E3810 + E3810 + PlaceboEisaiPhase 3

🔄Rabeprazole ER + RanitidineEisaiPhase 3

✅rabeprazole and pantoprazoleEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01264822	Pre-clinical	Completed	Jan 13, 2011	Nov 17, 2016	Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive
NCT01321567	Pre-clinical	Completed	Jan 1, 2011	Aug 1, 2013	Refractory Reflux Esophagitis
NCT00855361	Phase 1	Completed	Jul 1, 2009	Dec 1, 2011	Gastroesophageal Reflux
NCT00747695	Phase 1	Completed	Mar 1, 2008	Sep 1, 2009	GERD
NCT01286194	Pre-clinical	Completed	Apr 1, 2006	Jan 1, 2007	Frequent Heartburn
NCT00236184	Phase 3	Completed	Oct 1, 2005	Jun 1, 2008	Heartburn
NCT00132496	Phase 2	Completed	Aug 1, 2005	Jul 1, 2006	Gastroesophageal Reflux Disease

Competing Products

20 competing products in Gastroesophageal Reflux Disease

See all competitors

Product	Company	Stage	Hype Score
Ramucirumab + Paclitaxel + Placebo	Eli Lilly	Phase 3	40
Ramucirumab + Paclitaxel + Sacituzumab Tirumotecan + Rescue Medications + HER3-DXd	Daiichi Sankyo	Phase 1/2	39
Trastuzumab Deruxtecan	Daiichi Sankyo	Phase 2	35
zolbetuximab	Astellas Pharma	Pre-clinical	30
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracil	Astellas Pharma	Phase 3	44
zolbetuximab	Astellas Pharma	Pre-clinical	33
epirubicin + oxaliplatin + capecitabine + zolbetuximab	Astellas Pharma	Phase 2	35
zolbetuximab + oxaliplatin + capecitabine + placebo	Astellas Pharma	Phase 3	44
Famotidine	Astellas Pharma	Phase 2/3	38
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + Placebo	Astellas Pharma	Phase 3	47
Gentuximab + Paclitaxel	Sun Pharmaceutical	Phase 1/2	28
E3810 + E3810 + Placebo	Eisai	Phase 3	40
Rabeprazole ER + Ranitidine	Eisai	Phase 3	40
E3710 + E3710	Eisai	Phase 1	29
rabeprazole and pantoprazole	Eisai	Approved	43
Rabeprazole 20 mg	Eisai	Phase 2	35
RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUM	Eisai	Phase 3	40
Rabeprazole sodium + Esomeprazole	Eisai	Phase 3	40
rabeprazole sodium + Placebo	Eisai	Phase 3	40
Rabeprazole + Rabeprazole + Rabeprazole + Rabeprazole	Eisai	Phase 3	40